IMV - IMV STOCK NEWS

IMV Inc. announced Michael P. Bailey, President and CEO of AVEO Oncology, as the new Chairman of the Board, effective May 1, 2022. Bailey, who has been with IMV's Board since 2020, will guide the company into late-stage clinical development and enhance business opportunities for their DPX platform. His extensive experience in oncology, highlighted by previous successes at AVEO, Synta Pharmaceuticals, and ImClone Systems, will be pivotal for IMV's growth. Bailey succeeds Andy, who has served as Chairman since 2016.

IMV Inc. announced promising safety and efficacy results from a Phase 2 study combining maveropepimut-S (MVP-S) with pembrolizumab for advanced bladder cancer patients. Of 17 patients, 5 showed clinical responses, including 2 complete responses, especially among those previously treated with immune checkpoint inhibitors. The combination therapy was well-tolerated, with most adverse events being grade 1 or 2. Discussions with key opinion leaders are ongoing to explore further clinical opportunities.

IMV Inc. (NASDAQ: IMV) announced its participation at the IMMUNOLOGY™ 2022 meeting, held from May 6-10, 2022, in Portland, Oregon. The company will present a poster titled “Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy”, showcasing research by Dr. Brennan Dirk on May 7. IMV is advancing cancer therapies through its DPX® platform, with MVP-S in trials for various cancers, including DLBCL, ovarian, bladder, and breast cancers.

IMV Inc. (NASDAQ: IMV) announced participation in two significant events: the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, featuring presentations and one-on-one investor meetings, and the Wells Fargo Biotech Forum on April 12-13, 2022, focused on one-on-one investor meetings. IMV's lead therapy, maveropepimut-S, is in clinical trials for various cancers. The Needham conference presentation will be available for replay on the company's website for 90 days.

IMV announced significant developments regarding its clinical trials and financial results. The first patient was dosed in the VITALIZE Phase 2B trial for relapsed/refractory DLBCL, with early data from this trial anticipated in summer 2022. The company reported a cash position of $38.6 million, sufficient to fund operations into Q2 2023, despite increased operational costs of $39 million. Notably, the company aims to register MVP-S based on positive clinical data across multiple cancers. Upcoming milestones include presentations at AACR in April and the initiation of the AVALON ovarian cancer trial.

IMV Inc. (NASDAQ: IMV) announces a conference call on March 17, 2022 at 8:00 a.m. ET to discuss its 2021 fiscal year-end and fourth quarter financial results. The call is aimed at financial analysts, with access via phone or a live audio webcast available on the company's website. IMV is focused on developing immune-educating therapies using its novel DPX platform for treating various cancers, including ongoing clinical trials for its lead candidate, maveropepimut-S, in multiple indications.

IMV Inc. will present significant findings at the AACR Annual Meeting on its DPX technology, which enhances anti-tumor immune responses involving natural killer (NK) cells. The presentations include data from a Phase 2 basket study evaluating maveropepimut-S in combination with pembrolizumab and cyclophosphamide for advanced bladder cancer. Key insights will be shared by Dr. Olivier Rixe, highlighting the safety and efficacy of their immunotherapeutic strategies. IMV's platform aims to improve cancer treatment outcomes by activating targeted immune responses.

IMV Inc. (NASDAQ: IMV) will host a Research and Development Day via webcast on February 24, 2022, at 8:00 am ET. The event will showcase its patented DPX technology for developing immune-educating therapies aimed at treating various cancers. Michael Kalos, Ph.D., an expert in T cell therapy, will present the platform's capabilities in oncology. IMV will also update its clinical programs and expected milestones for 2022, followed by a live Q&A session. Registration details are available on their website.

IMV Inc. has initiated the VITALIZE Phase 2B clinical trial, dosing its first patient with maveropepimut-S (MVP-S) in combination with KEYTRUDA. This study aims to evaluate the efficacy of MVP-S for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial will also assess the immunomodulatory role of low-dose cyclophosphamide. The primary endpoint is the Objective Response Rate (ORR), with results expected in summer 2022, building on positive findings from the previous SPiReL trial.